glp-1 hair loss prevention One of the most common concerns I'm seeing in patients taking medications is loss. For some, it shows up as increased shedding; for others, it can be more dramatic with Supports fuller Follow for evidence-based GLP-1 guidance

Rodrguez-Bentez P et al

Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Athiras lead clinical candidate, fosgonimeton (formerly ATH-1017 / NDX-1017), is a structurally distinct phosphate prodrug of Dihexa not Dihexa itself

CrossRef Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunctionassociated steatotic liver disease Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru Frontiers in Epidemiology .2026;[Epub] CrossRef Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review Karol P

" The group did applaud the FDA for providing an off-ramp to help avoid an interruption of therapy for patients, the trade group said